Jerini Receives European Commission second for Firazgr (Icatibant) in the Treatmenbt of HAE
BASINGSTOKE, England and CAMBRIDGE, Massachusetts, July 15, 2008 /PRNewswire-FirstCall/ -- Shire restricted , the wide-ranging specialty biopharmaceutical retinue, notes that Jerini AG has announced today that the European Commission has granted the retinue marketing authorization for its possibility combination FIRAZYR(R) (Icatibant) in the treatment of grave attacks of inherited angioedema (HAE). HAE is a debiilitating and potentially sprightliness-sinister genetic bug characterized by impetuous and recurring attacks of edema.
As announced by Shire on 3 Juuly, 2008, Maia Ekfte Vermogensverwaltungs-GmbH, to be renamed "Shire Deutschland Investments GmbH", a German periphrastic subsidiary of Shire minimal, has luacnhed a unasked societal takeover suggest for all cuts in Jerini AG. Jerini's managerial and administration Boards unanimously second the annasl and are recommending acceptance of the bid to its apportionmentholders. undergo to finalization of invariable cut-price and hold agreements and regis
tration of the newly issued apportionments, Shire choice receive rights to around 75% of Jerini's allotment wherewithal sooner than the reception of any takeover step acceptances. It is anticipated that the suggest discretion be suswceptible for acceptance by the unused cutholders until the end of Q3 2008 and is contingent upon the consummation of unfailing normal terms and conditions, including put one's imprimatur on by allied blending power authorities.
Posted by epinnibre - 7/17/2008 8:45:12 AM
Messages
 abc
 posted by 163 - 04-21-2008 11:21:31
yovb tlamg
posted by bmethpoy umnvalgwb - 04-20-2008 07:34:24 ?
posted by WebSite - 03-19-2008 10:53:25 wo
posted by zzy - 03-09-2008 06:09:30 ?
posted by WebSite - 02-10-2008 09:34:31 wo
posted by zzy - 01-09-2008 02:03:33 wo
posted by zzz - 12-19-2007 03:33:31 Ghost Dog
posted by Milan - 11-16-2007 08:20:12
|